Imaging of inflammation in the cortex of the brain in progressive MS p
Grey matter microglial imaging with [18F]DPA-714 in progressive MS patients
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Dpa-714
What it measured
Main measures
The main study parameter is the [18F]DPA-714 binding potential (BP) which will be assessed in PPMS and SPMS patients and healthy control subjects with validated tracer kinetic models. BP is a measurement of microglial activation.
Smouldering inflammation
Other measures (1)
- The relation between [18F]DPA-714 BP in the cerebral cortex and/or hippocampus and MRI detected grey matter lesions and cortical thinning.
MRI lesions
Who could take part
Progressive MS · EDSS 4.0 to 7.5
Show the full criteria
Inclusion criteria
Inclusion: - For the MS patient group: diagnosis primary or secondary progressive MS with EDSS scores 4.0 to 7.5 - 18 to 60 years Exclusion: - Inability to undergo MRI, e.g. metal objects in or around the body, claustrophobia or inability to lie still in the scanner. For the MS patients: contra-indication for gadolinium administration, e.g. previous allergic reaction to gadolinium.
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The aim of this pilot study is to determine whether uptake op the TSPO radioligand [18f}DPA-714 can be quantified in the cortex and/or hippocampus in vivo to discriminate progressive MS patients from controls.
Loading reviews and guidelines…
Related trials
- Novel Imaging Markers in SPMS
Early phase 1 · Completed
No results found
- Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predictin
Completed
Results posted, not judged
- Validation of the 18 kiloDalton Translocator Protein (TSPO) as a Novel
Not a drug-phase study · Status unknown
No results found
History
Started
Dec 2014